Markets:

Overview

News

Currencies

International

Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

15.96 -0.29 (-1.82%)

Streaming Delayed Price Updated: 11:20 AM EDT, May 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Cognitive Drugs Market Expected Reach Revenues Of $21 Billion in 2027

April 13, 2022

Palm Beach, FL – April 13, 2022 – FinancialNewsMedia.com News Commentary – Dementia is the loss of cognitive functioning, thinking, remembering, reasoning, and behavioral abilities to such an extent...

Via FinancialNewsMedia

Takeda Announces Completion of Acquisition of Own Shares

April 13, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

FDA Approves Takeda's Vonvendi As Prophylactic Treatment In Bleeding Disorder ↗

January 31, 2022

The

Via Benzinga

The Daily Biotech Pulse: Aeglea Stock Jumps On Inherited Metabolic Disease Data, Partial Hold Lifted On Gilead's 2 Blood Trials, Early Data From Novartis' KRAS Inhibitor And More ↗

April 12, 2022

Here's a roundup of top developments in the biotech space over the last 24 hours:

Via Benzinga

Takeda’s TAKHZYRO® (lanadelumab) Open Label Phase 3 Study Met Its Objectives in Children Ages 2 to <12 Years of Age With Hereditary Angioedema (HAE)

April 12, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda and the New York Academy of Sciences Announce 2022 Innovators in Science Award Winners

April 05, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Monday Markets News ↗

March 28, 2022

Japanese Takeda TAK shares failed to thrive after its edema prevention drug was approved.

Via Talk Markets

Takeda’s TAKHZYRO® (lanadelumab) Approved in Japan for Prophylaxis Against Acute Attacks of Hereditary Angioedema (HAE)

March 28, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda's Angioedema Drug Shows Promising Action Against COVID-19 Infection ↗

March 08, 2022

Takeda Pharmaceutical Co Ltd's (NYSE: TAK) Firazyr (icatibant), used to treat a blood vessel condition called angioedema, has shown promise as a treatment for COVID...

Via Benzinga

Interim Phase 4 Data Support TAKHZYRO® (lanadelumab) as an Effective Treatment to Reduce Attacks in Hereditary Angioedema Patients

February 28, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Roche And AstraZeneca Settle Ultomiris Patent Lawsuit ↗

February 22, 2022

Roche Holdings AG (OTC: RHHBY) has decided to close out a patent infringement lawsuit against AstraZeneca plc (NASDAQ: AZN), centering around the latter's newly...

Via Benzinga

Takeda Inks $2B Gene Therapy Pact With Code Biotherapeutics ↗

February 22, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) has signed up for a gene therapy pact, encoding a $2 billion biobucks deal with Code Biotherapeutics across four...

Via Benzinga

Real-World Analysis Show Takeda's Alofisel Clinical Remission Rate At Six-Months ↗

February 18, 2022

Takeda Pharmaceutical Co Ltd (NYSE: TAK) announced the first six-month interim analysis results from INSPIRE study evaluating the Real-World Effectiveness and Safety of...

Via Benzinga

Alofisel®▼ (darvadstrocel) Shows Clinical Remission Rate at Six-Months in the Real-World INSPIRE Study Interim Analysis Consistent with the Pivotal Clinical ADMIRE-CD Study1,2

February 18, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

The Best Russell 2000 Stocks to Buy Before they Rebound ↗

February 15, 2022

Some of the best stocks in the market are among the best Russell 2000 stocks to buy. Here's a list of a few of those choices.

Via InvestorPlace

Why Are Seagen Shares Sinking Today? ↗

February 10, 2022

Seagen Inc (NASDAQ: SGEN) reported Q4 revenues

Via Benzinga

Take a Leap Into Novavax Stock After Vaccine Sales Start ↗

February 08, 2022

Novavax is worth speculating on at current levels. NVAX stock has fallen below the $100 mark ahead of its global Covid-19 vaccine launch.

Via InvestorPlace

A News Blizzard ↗

February 04, 2022

Markets are still down despite very encouraging news in January when 467,00 new hires got jobs.

Via Talk Markets

Takeda Delivers Strong Third Quarter FY2021 Results and Raises Full-Year Forecast Reflecting Strong Momentum

February 03, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

FDA Approves Prophylactic Treatment with VONVENDI® [von Willebrand Factor (Recombinant)] for Adult Patients Living with Severe Type 3 von Willebrand Disease (VWD)

January 31, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Worldwide Adoption of Novavax Vaccines Makes It a Winner ↗

January 21, 2022

Novavax can still generate billions of dollars of revenue per year from its shot, making NVAX stock quite attractive at its current levels.

Via InvestorPlace

Takeda Named Global Top Employer for Fifth Consecutive Year

January 19, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

More Serious Matters ↗

January 14, 2022

Wall Street fell on new worries about inflation and a drop in retail sales levels.

Via Talk Markets

Denali Stock Tumbles; Why Biogen Isn't The Only Alzheimer's Play Under Pressure ↗

January 13, 2022

Denali Therapeutics is under pressure after the FDA put its study on hold.

Via Investor's Business Daily

Interest Rate Hikes And Stocks ↗

January 12, 2022

Abnormal flooding in northwest Brazil has blocked iron ore mining which resulted in a jump in the price of ore.

Via Talk Markets

Takeda to Acquire Adaptate Biotherapeutics to Develop Novel Gamma Delta (γδ) T Cell Engager Therapies Targeting Solid Tumors

January 10, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Takeda Emphasizes Strategy for Delivering Sustainable Growth Over Next Decade at the 40th Annual J.P. Morgan Healthcare Conference

January 10, 2022

From Takeda Pharmaceutical Company Limited

Via Business Wire

Post-Fed Thursday ↗

January 06, 2022

Companies earning in dollars but incorporated abroad and paying dividends in other currencies were big gainers today.

Via Talk Markets

FDA Rejects Takeda's Eosinophilic Esophagitis Candidate, Asks For Additional Study ↗

December 22, 2021

Takeda Pharmaceutical Co Ltd (NYSE: TAK) received a Complete Response Letter (CRL) from the FDA for its marketing application for TAK-721 (budesonide oral...

Via Benzinga

The Daily Biotech Pulse: Allakos Slips Negative Late-Stage Data, Pfizer & Merck Announce Fresh COVID Pill Deal With UK, Regulatory Setback For Takeda ↗

December 22, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Stocks In Focus Allakos's Lirentelimab Flunks Late-Stage Studies In Patients With...

Via Benzinga

< Previous 1 2

...

13 14 15 16 17 18 19 20 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.